NEW YORK, Nov. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company’s initial public offering conducted between February 9 and 13, 2024 (the “IPO”), of the important November 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Metagenomi stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company’s initial public offering conducted between February 9 and 13, 2024 (the “IPO”), of the important November 25, 2024 lead plaintiff deadline. SO WHAT: If you purchased Metagenomi stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

Core Viewpoint - Metagenomi, Inc. is facing a class action lawsuit following the termination of its collaboration with Moderna, which was a significant aspect of its initial public offering narrative [2]. Group 1: Company Overview - Metagenomi, Inc. is characterized as a "genetic medicines company" and had a strategic collaboration with Moderna, which was highlighted during its initial public offering [2]. - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [2]. Group 2: Key Events - On May 1, 2024, Metagenomi announced the mutual termination of its collaboration agreement with Moderna, which was unexpected and raised concerns about the company's future [2]. - Following the announcement, Metagenomi's stock price fell from $7.04 per share on May 1, 2024, to $6.17 per share on May 2, 2024, indicating a significant market reaction to the news [2]. Group 3: Legal Proceedings - A class action lawsuit has been initiated for shareholders who purchased shares during the IPO period from February 9 to 13, 2024, with a deadline for registration set for November 25, 2024 [3]. - Shareholders are encouraged to register for the class action to receive updates and monitor the case's progress [3].

Core Points - A shareholder class action lawsuit has been filed against Metagenomi, Inc. alleging that the company made materially false and misleading statements regarding its collaboration agreement with Moderna, which harmed investors [1] - The lawsuit specifically targets investors who purchased shares of Metagenomi on or after February 13, 2024, and experienced significant losses [2] - The deadline for investors to request to be appointed as lead plaintiff in the case is November 25, 2024 [3]

Core Points - Metagenomi, Inc. (NASDAQ: MGX) is facing a class action lawsuit following the termination of its collaboration with Moderna, which was a significant aspect of its business model [3][4] - The company completed its initial public offering (IPO) on February 13, 2024, selling 6.25 million shares at $15 per share, but the stock price fell from $7.04 to $6.17 within a day after the announcement of the collaboration termination [3] Group 1 - The lawsuit is on behalf of shareholders who purchased stock during the class period from February 9 to 13, 2024, related to Metagenomi's IPO [2][4] - The termination of the collaboration with Moderna was unexpected and raised concerns about Metagenomi's future prospects [3] - The Gross Law Firm is leading the class action, emphasizing its commitment to protecting investors' rights against deceitful practices [5] Group 2 - Shareholders are encouraged to register for the class action by November 25, 2024, to potentially become lead plaintiffs [4] - The firm offers portfolio monitoring software to keep registered shareholders updated on the case's progress [4] - The lawsuit highlights the importance of accurate disclosures and the impact of misleading statements on stock performance [5]

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Metagenomi securities pursuant and/or traceable to Metagenomi's registration statement for the initial public of ...

PHILADELPHIA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Metagenomi Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX) on behalf of purchasers of Metagenomi securities between February 6, 2024 and September 26, 2024, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired METAGENOMI securities during the Class Period may, no later than NOVEMBER 25, 2024, seek to be appointed as a lead pla ...

Group 1 - The lawsuit is on behalf of shareholders who purchased Metagenomi, Inc. (NASDAQ: MGX) shares during the initial public offering (IPO) period from February 9 to 13, 2024 [1] - Metagenomi's IPO involved selling 6.25 million shares at a price of $15 per share, and the company claimed a significant partnership with Moderna, which was a key aspect of its business model [2] - The collaboration with Moderna was terminated on May 1, 2024, leading to a decline in Metagenomi's stock price from $7.04 to $6.17 per share within a day [2] Group 2 - Shareholders are encouraged to register for the class action lawsuit by November 25, 2024, to potentially become lead plaintiffs and receive updates on the case [3] - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Metagenomi stock between February 9 and 13, 2024, may be eligible for compensation without any out-of-pocket costs through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 25, 2024 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] Group 2: Company Background and Allegations - Metagenomi presented itself as a "genetic medicines company" with a significant partnership with Moderna during its IPO [4] - The collaboration with Moderna included a Strategic Collaboration and License Agreement established on October 29, 2021, which involved multiple research programs [4] - Following the IPO, Metagenomi announced the termination of its collaboration with Moderna on May 1, 2024, leading to claims of investor damages when the true details became public [4]

NEW YORK, Nov. 2, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of Metagenomi, Inc. (NASDAQ: MGX) pursuant and/or traceable to the Company's initial public offering conducted between February 9 and 13, 2024 (the "IPO"), of the important November 25, 2024 lead plaintiff deadline.So what: If you purchased Metagenomi stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.What to do ...